Who is sponsoring NCT05316818?

NCT05316818 is sponsored by Kasr El Aini Hospital.

What condition does NCT05316818 study?

NCT05316818 studies Metastatic Colorectal Cancer.

What drugs are being tested in NCT05316818?

Interventions: FOLFOXIRI Protocol.

What is the status of NCT05316818?

NCT05316818 is currently COMPLETED.

Last reviewed 2022-04-07 · How we verify

Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma

NCT05316818 PHASE2 COMPLETED

This is a prospective randomized phase II trial was done in clinical oncology department at Kasr Alainy hospital, Cairo university (NEMROCK) to evaluate the role of intensification of chemotherapy in the first line for treatment of metastatic colorectal carcinoma by adding third agent to standard doublet regimen on oncological outcomes \& assess tolerance to the intensified treatment

Details

Lead sponsor	Kasr El Aini Hospital
Phase	PHASE2
Status	COMPLETED
Enrolment	64
Start date	Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Apr 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Metastatic Colorectal Cancer

Interventions

FOLFOXIRI Protocol

Countries

Egypt